References
*Decreased CD4 lymphocyte count in a patient with a history of HIV infection and combined tibia–fibula fracture in a patient who received treatment with another FVIII product, which was prohibited during the study; †Hematochezia, alanine aminotransferase increase, asparate aminotransferase increase, FVIII level increase, VWF antigen increase.2 AE, adverse event; CD4, cluster of differentiation4; FVIII, factor VIII; SAE, serious adverse event; TESAE, treatment-emergent serious adverse event; VWF, von Willebrand factor.
- von Drygalski A et al. N Engl J Med 2023;388:310–8
- Malec L et al. N Engl J Med 2024;391:235–46
PP-34699